Perrigo Company plc PRGO reported adjusted earnings of 93 cents per share in the fourth quarter of 2024, beating the Zacks Consensus Estimate of 92 cents. The reported figure increased 8% year over year, primarily due to improved margins and lower variable expenses.

Net sales declined 1.6% year over year to $1.14 billion, missing the Zacks Consensus Estimate of $1.20 billion. The downside was due to the loss of sales stemming from exited businesses and product lines.

During the quarter, sales dropped 2.1% year over year on account of exited businesses and product lines and another 0.1% from unfavorable currency movement. At constant currency (excluding foreign currency translation), sales fell 1.5%. Organic net sales (excluding the effects of acquisitions and divestitures and the impact of currency) rose 0.7%.

See the Zacks Earnings Calendar to stay ahead of market-making news.

Year to date, shares of Perrigo have lost 6.1% against the industry’s 11% growth.

Image Source: Zacks Investment Research

More on PRGO’s Earnings

Perrigo reports its results under the following segments — Consumer Self Care Americas (CSCA) and Consumer Self Care International (CSCI).

CSCA: The segment’s net sales in the quarter came in at $744 million, flat year over year. Though sales grew across the Nutrition, Skin Care and Women's Health categories, sales in the Pain & Sleep Aids, Upper Respiratory and Digestive Health categories offset this growth. Organic net sales rose 0.1%.

CSCI: The segment reported net sales of $394 million, down 4.5% from the year-ago period’s levels due to product line exits and unfavorable currency movements. At constant currency rates, sales were down 4.1% year over year. Organically, sales increased 1.8%.

Full-Year 2024 Results

Perrigo reported revenues of $4.37 billion, down 6.1% year over year. Net sales also fell 4.5% organically.

The company reported adjusted earnings of $2.57 per share for 2024, down 0.4% year over year.

PRGO’s 2025 Guidance

Perrigo will be hosting a virtual Investor Day today, where management will share the company’s 2025-2027 strategic plan to boost performance. During the event, management will also issue its financial guidance for the full year 2025.

PRGO’s Zacks Rank

Perrigo currently has a Zacks Rank #3 (Hold).

Perrigo Company plc Price

Perrigo Company plc price | Perrigo Company plc Quote

Our Key Picks Among Biotech Stocks

Some better-ranked stocks are argenx ARGX, Pacira BioSciences PCRX and 89bio ETNB. While ARGX and PCRX sport a Zacks Rank #1 (Strong Buy) each at present, ETNB carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Estimates for argenx’s 2025 earnings per share (EPS) have increased from $2.07 to $3.13 over the past 60 days, while the same for 2026 has increased from $9.08 to $10.85. ARGX’s shares have gained 2% year to date.

argenx's earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 339.37%.

Estimates for Pacira BioSciences’ 2025 EPS have increased from $3.16 to $3.20 over the past 60 days, and the same for 2026 has risen from $2.79 to $3.59. PCRX’s shares have surged 35% year to date.

Pacira’s earnings beat estimates in two of the trailing four quarters, missed once and met in the other, delivering an average surprise of 7.13%.

Estimates for 89bio’s loss per share have narrowed from $3.22 to $3.19 for 2025 in the past 60 days. The loss per share estimate for 2026 has narrowed from $3.19 to $2.51 in the same time frame. ETNB’s shares have risen 19% year to date.

89bio’s earnings beat estimates in two of the trailing four quarters and missed in the other two, delivering a negative average surprise of 37.49%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Perrigo Company plc (PRGO) : Free Stock Analysis Report

Pacira BioSciences, Inc. (PCRX) : Free Stock Analysis Report

argenex SE (ARGX) : Free Stock Analysis Report

89BIO (ETNB) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research